EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public offering at $18 per share, raising approximately $318 million and marking a significant milestone for the biotech company. The IPO gives Aktis a targeted valuation of up to $945.4 million, highlighting strong investor appetite for innovative oncology-focused biotechnology firms despite ongoing volatility in the public markets.
Aktis Oncology focuses on developing next-generation cancer therapies designed to improve outcomes for patients with hard-to-treat tumors. The company’s IPO comes at a time when investor interest in biotechnology and life sciences is gradually rebounding, driven by demand for differentiated pipelines, precision medicine, and novel therapeutic approaches. By upsizing the offering, Aktis demonstrated confidence in its growth strategy and long-term clinical potential.
The IPO priced at the top end of expectations, reflecting robust demand from institutional investors seeking exposure to oncology drug development. Proceeds from the offering are expected to support ongoing clinical trials, research and development activities, and potential expansion of Aktis’ drug pipeline. The capital raise also strengthens the company’s balance sheet as it advances its lead programs toward key regulatory and clinical milestones.
Aktis’ near-billion-dollar valuation places it among notable recent biotech IPOs and underscores the market’s willingness to back companies with compelling science and experienced leadership teams. Analysts note that oncology remains one of the most attractive segments within the pharmaceutical and biotech sectors due to unmet medical needs and the potential for high-value drug approvals.
The successful IPO of Aktis Oncology may encourage other cancer drug developers and biotech startups to consider going public, especially as market conditions stabilize. For investors, the offering signals renewed confidence in innovation-driven biotech companies with strong clinical prospects. As Aktis Oncology begins trading on U.S. markets, attention will remain on its clinical progress, pipeline updates, and ability to deliver long-term value in the competitive cancer drug development landscape.
